What is Automata?
Automata operates at the intersection of robotics, software engineering, and life sciences. The company provides an integrated lab automation platform designed to eliminate the bottlenecks associated with manual laboratory processes. By combining modular hardware benches with sophisticated orchestration software, Automata enables clinical and research laboratories to achieve higher throughput, improved data integrity, and enhanced reproducibility. Its market position is defined by its ability to transform static laboratory environments into dynamic, automated ecosystems, which is increasingly vital for the rapid development of therapeutics and diagnostic tools. As the demand for high-quality data in drug discovery grows, Automata's technology serves as a foundational layer for organizations seeking to optimize their operational efficiency and scientific output.
How much funding has Automata raised?
Automata has raised a total of $142.4M across 4 funding rounds:
Series A
$7.4M
Series B
$50M
Other Financing Round
$40M
Series C
$45M
Series A (2019): $7.4M, investors not publicly disclosed
Series B (2022): $50M led by ABB Technology Ventures, Hummingbird, Octopus Ventures, Isomer Capital, and Latitude Ventures
Other Financing Round (2023): $40M supported by Isomer Capital, Octopus Ventures, Aldea Ventures, Hummingbird, and Possible Ventures
Series C (2026): $45M featuring Octopus Ventures, Entrepreneur First, Tru Arrow Partners, and Danaher
Key Investors in Automata
Octopus Ventures
Octopus Ventures is a founder-focused venture capital firm backing people and ideas that aim to change the world, investing in mission-driven companies across software, climate, health, consumer, and financial technology.
Danaher
Danaher Corporation operates across the biotechnology, life sciences, and diagnostics sectors, delivering integrated solutions that enable the development and manufacture of therapeutic products globally.
Isomer Capital
Isomer Capital is a venture capital firm dedicated to supporting early-stage technology companies across Europe, focusing on building a robust ecosystem through direct co-investments and strategic partnerships.
What's next for Automata?
With the successful completion of this major strategic investment, Automata is well-positioned to expand its footprint in the global life sciences market. The company's strategic roadmap likely involves scaling its manufacturing capabilities to meet rising demand and enhancing its software orchestration suite to support more complex, multi-disciplinary workflows. Furthermore, the involvement of strategic partners suggests a focus on deeper integration within the pharmaceutical and clinical diagnostic supply chains. As Automata moves into this next phase of growth, the focus will remain on maintaining its competitive edge through continuous innovation in robotics and data-driven laboratory management, ensuring that it remains the partner of choice for organizations aiming to modernize their research and development infrastructure.
See full Automata company page
